Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

• Published in: The lancet oncology Vol. 22; no. 4; pp. 512 - 524
• Main Authors: Kuruvilla, John, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A, Fogliatto, Laura Maria, Goncalves, Iara, de Oliveira, Jose S R, Buccheri, Valeria, Perini, Guilherme F, Goldschmidt, Neta, Kriachok, Iryna, Dickinson, Michael, Komarnicki, Mieczyslaw, McDonald, Andrew, Ozcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Nahar, Akash, Marinello, Patricia, Zinzani, Pier Luigi
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2021; Elsevier Limited
• Subjects: Adolescent; Adult; Adverse events; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Autografts; Brentuximab Vedotin - administration & dosage; Brentuximab Vedotin - adverse effects; Creatinine; Dehydrogenases; Female; Hematology, Oncology, and Palliative Medicine; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic stem cells; Hodgkin Disease - drug therapy; Hodgkin Disease - pathology; Hodgkin's lymphoma; Humans; Hypothyroidism; Immunoconjugates - administration & dosage; Immunotherapy; Leukocytes (neutrophilic); Lymphoma; Male; Medical prognosis; Middle Aged; Monoclonal antibodies; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Neutropenia; Patients; PD-1 protein; Pembrolizumab; Peripheral neuropathy; Pneumonitis; Progression-Free Survival; Proportional Hazards Models; Statistical analysis; Stem cell transplantation; Targeted cancer therapy; Toxicity; Treatment Outcome; Young Adult

PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory class...